FUT-175の血液透析用局所抗凝固薬としての臨床評価

DOI

書誌事項

タイトル別名
  • Clinical evaluation of FUT-175 as a regional anti-coagulant in hemodialysis
  • Multi-center cooperative study
  • 多施設共同研究

説明

One hundred and seven hemodialysis (HD) patients with high bleeding risk were treated with nafamostat mesilate (FUT-175; FUT) as an anti-coagulant for HD for about 16 days (HD=7.5 times). With the optimum dose of FUT, estimated to be 34.2±1.2mg/hr, the residual blood volumes in dialyzers after HD were less than those with low dose heparinization. Celite activated coagulation times (CCT) during HD, measured in the systemic circulation, were not prolonged. However, in the extracorporeal circuit, the CCT were increased the same as it was with heparin. The CCT 15min after the end of HD was not increased and with FUT the hemostatic time was shortened at the puncture site after the removal of the needle. The exacerbation of the bleeding by HD occurred in only 21 out of 573 HD procedures (3.7%). And 134 of 145 HD (92.4%) with active bleeding were completed without exacerbating the bleeding. There were six cases (5.6%) of adverse effects of FUT in 10 HD procedures (1.2%). At the end of the study, FUT was considered to be an effective, safe and useful drug as a regional anti-coagulant for HD in 95.3, 97.2 and 94.4% of the patients examined, respectively. These results indicate that FUT is a very useful anti-coagulant for HD, especially in patients with high bleeding risk.

収録刊行物

キーワード

詳細情報 詳細情報について

  • CRID
    1390001204677363456
  • NII論文ID
    130003873965
  • DOI
    10.4009/jsdt1985.20.951
  • ISSN
    18846211
    09115889
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ